Last year, the FDA issued separate draft guidance for medical devices that would allow manufacturers in the initial premarket submission of a product to essentially pre-specify future capabilities of a device without resubmitting it later for approval.

AI and machine learning can extract data from electronic health records and other sources and make inferences useful in everything from how a drug may affect certain patients to optimizing dosing.